3/28/2024

Janusmed kön och genus

Janusmed kön och genus – Montelukast Krka

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Montelukast

Montelukast

Klass : A

  1. Dales RE, Mehdizadeh A, Aaron SD, Vandemheen KL, Clinch J. Sex differences in the clinical presentation and management of airflow obstruction. Eur Respir J. 2006;28:319-22.
  2. Tantisira KG, Colvin R, Tonascia J, Strunk RC, Weiss ST, Fuhlbrigge AL et al. Airway responsiveness in mild to moderate childhood asthma: sex influences on the natural history. Am J Respir Crit Care Med. 2008;178:325-31.
  3. Singulair (montelukast). DailyMed [www]. US National Library of Medicine. [updated 2016-06-30, cited 2017-05-28].
  4. Food and Drug Aministration (FDA). Clinical Pharmacology and Biopharmaceutics Review - SINGULAIR (montelukast sodium). Food and Drug Administration [www]. [updated 2005-07-12, cited 2017-05-28].
  5. Cheng H, Leff JA, Amin R, Gertz BJ, De Smet M, Noonan N et al. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res. 1996;13:445-8.
  6. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108:E48.
  7. Johnston NW, Mandhane PJ, Dai J, Duncan JM, Greene JM, Lambert K et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics. 2007;120:e702-12.
  8. Virchow JC, Mehta A, Ljungblad L, Mitfessel H. A subgroup analysis of the MONICA study: a 12-month, open-label study of add-on montelukast treatment in asthma patients. J Asthma. 2010;47:986-93.
  9. Rabinovitch N, Strand M, Stuhlman K, Gelfand EW. Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast. J Allergy Clin Immunol. 2008;121:1365-71.
  10. Dunn RM, Lehman E, Chinchilli VM, Martin RJ, Boushey HA, Israel E et al. Impact of Age and Sex on Response to Asthma Therapy. Am J Respir Crit Care Med. 2015;192:551-8.
  11. Bygdell M, Brunlöf G, Wallerstedt SM, Kindblom JM. Psychiatric adverse drug reactions reported during a 10-year period in the Swedish pediatric population. Pharmacoepidemiol Drug Saf. 2012;21:79-86.
  12. Singh SB, Weinberger MM, Zimmerman MB, Starner TD. Growth of preschool age children receiving daily inhaled corticosteroids. Allergy Asthma Proc. 2013;34:511-8.
  13. Ingelsson E, Yin L, Bäck M. Nationwide cohort study of the leukotriene receptor antagonist montelukast and incident or recurrent cardiovascular disease. J Allergy Clin Immunol. 2012;129:702-707e2.
  14. Bollinger ME, Diette GB, Chang CL, Stephenson JJ, Sajjan SG, Fan T et al. Patient characteristics and prescription fill patterns for allergic rhinitis medications, with a focus on montelukast, in a commercially insured population. Clin Ther. 2010;32:1093-102.
  15. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2016 [cited 2017-06-20.]